1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino]

Request For Quotation
1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] Suppliers list
Company Name: Shanghai Sphchem Co., Ltd.  
Tel: 021-56491756 13512199871
Email: 2819742715@qq.com
Company Name: Shanghai Maruhua Science and Technology Co. Ltd.  
Tel: 18721745940
Email: sales2@api-chem.com
Company Name: changzhou ansciep chemical co., ltd.  
Tel: 0519-86305871 13961213398;
Email: tina@ansciepchem.com
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Email: 486064515@qq.com
Company Name: Hubei wei shi reagent group ltd., company  
Tel: 027-59102966 18717199209
Email: 2853877583@qq.com
1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] Basic information
Product Name:1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino]
Synonyms:1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino];3-(3-Hydroxyphenyl)-1-methyl-7-((3-(4-methylpiperazin-1-yl)phenyl)amino)-1,6-naphthyridin-2(1H)-one;UH15-38
CAS:2540881-21-6
MF:C26H27N5O2
MW:441.53
EINECS:
Product Categories:
Mol File:2540881-21-6.mol
1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] Structure
1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] Chemical Properties
Boiling point 650.3±55.0 °C(predicted)
density 1.297±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
solubility DMSO: Soluble: =10 mg/ml
Ethanol: Sparingly soluble: 1-10 mg/ml
pka9.50±0.10(predicted)
form Solid
color White to light yellow
Safety Information
MSDS Information
1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] Usage And Synthesis
UsesUH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury[1].
in vivo

UH15-38 (30 mg/kg; i.p.; daily for 4 days) dampens IAV (influenza A virus)-induced lung injury[1].

Animal Model:C57Bl/6 mice (lethal dose of PR8 (6,000×EID50))[1]
Dosage:30 mg/kg
Administration:I.p.; once daily for 4 days; starting 24h after infection
Result:Markedly reduced numbers of pMLKL+ necroptotic cells, decreased in diffuse alveolar damage and the formation of hyaline membranes, reduced the extent of fibrotic lung damage, displayed significantly lower levels of the pro-fibrotic mediators (IL-1β, IL-6, IL-18, IL-17 and CCL5).
IC 50RIPK3: 20 nM (IC50)
References[1] Gautam A, et al. Necroptosis blockade prevents lung injury in severe influenza. Nature. 2024 Apr;628(8009):835-843. DOI:10.1038/s41586-024-07265-8
1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] Preparation Products And Raw materials
Tag:1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino](2540881-21-6) Related Product Information
GSK872 Necrostatin-5 3-(1,3-benzothiazol-5-yl)-7-(1,3-dimethyl-1H-pyrazol-5-yl)thieno[3,2-c]pyridin-4-amine Thapsigargin Benzeneacetamide, N-[5-[[2-[[[4-[(ethylsulfonyl)amino]cyclohexyl]carbonyl]amino]-5-fluoro-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)- HA/Hemagglutinin Protein, H12N1 (ABB88099, sf9, His)